A5086655631- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Cardiac Valve Diseases and Treatments
- Cardiovascular Disease and Adiposity
- Cardiac pacing and defibrillation studies
- Cardiac Arrhythmias and Treatments
- Pulmonary Hypertension Research and Treatments
- Cardiomyopathy and Myosin Studies
- Cardiac Structural Anomalies and Repair
- Cardiovascular and Diving-Related Complications
- Infective Endocarditis Diagnosis and Management
- Adipose Tissue and Metabolism
- Hemoglobinopathies and Related Disorders
- Cardiac Ischemia and Reperfusion
- Atrial Fibrillation Management and Outcomes
- Cardiac electrophysiology and arrhythmias
- Advanced MRI Techniques and Applications
- Iron Metabolism and Disorders
- Cardiovascular Effects of Exercise
- Telomeres, Telomerase, and Senescence
- Transplantation: Methods and Outcomes
- Aortic Disease and Treatment Approaches
- Mitochondrial Function and Pathology
- Acute Myocardial Infarction Research
- Blood Pressure and Hypertension Studies
Inserm
2016-2025
Université Paris-Est Créteil
2016-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Centre Hospitalier Universitaire Henri-Mondor
1998-2025
Institut Mondor de Recherche Biomédicale
2014-2024
Tufts Medical Center
2024
Hôpitaux Universitaires Henri-Mondor
2015-2024
Hospices Civils de Lyon
2011-2024
Hôpital Albert-Chenevier
2021-2024
Biomedical Research Institute
2024
The ESH/ESC Guidelines represent the views of ESH and ESC were arrived at after careful consideration available evidence time they written.Health professionals are encouraged to take them fully into account when exercising their clinical judgement.The guidelines do not, however, override individual responsibility health make appropriate decisions in circumstances patients, consultation with that patient, where necessary patient's guardian or carer.It is also professional's verify rules...
Background— The design of a percutaneous implantable prosthetic heart valve has become an important area for investigation. A percutaneously implanted (PHV) composed 3 bovine pericardial leaflets mounted within balloon-expandable stent was developed. After ex vivo testing and animal implantation studies, the first human performed in 57-year-old man with calcific aortic stenosis, cardiogenic shock, subacute leg ischemia, other associated noncardiac diseases. Valve replacement had been...
Patent foramen ovale and atrial septal aneurysm have been identified as potential risk factors for stroke, but information about their effect on the of recurrent stroke is limited. We studied risks cerebrovascular events associated with these cardiac abnormalities.A total 581 patients (age, 18 to 55 years) who had an ischemic unknown origin within preceding three months were consecutively enrolled at 30 neurology departments. All received aspirin (300 mg per day) secondary prevention.After...
Experimental evidence suggests that cyclosporine, which inhibits the opening of mitochondrial permeability-transition pores, attenuates lethal myocardial injury occurs at time reperfusion. In this pilot trial, we sought to determine whether administration cyclosporine percutaneous coronary intervention (PCI) would limit size infarct during acute infarction.We randomly assigned 58 patients who presented with ST-elevation infarction receive either an intravenous bolus 2.5 mg per kilogram body...
Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic and echocardiographic features representing risk would benefit from PFO or anticoagulation, as compared antiplatelet therapy.In a multicenter, randomized, open-label trial, we assigned, in 1:1:1 ratio, 16 60 years age who had recent attributed PFO, an associated atrial septal aneurysm large interatrial shunt, transcatheter plus long-term therapy...
The incidence of embolic events (EE) and death is still high in patients with infective endocarditis (IE), data about predictors these 2 major complications are conflicting. Moreover, the exact role echocardiography risk stratification not well defined. In a multicenter prospective European study, including 384 consecutive (aged 57+/-17 years) definite IE according to Duke University criteria, we tested clinical, microbiological, echocardiographic as potential EE 1-year mortality....
Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury reduce myocardial infarct size. We aimed to test whether would improve outcomes prevent adverse left ventricular remodeling.In a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset had complete occlusion of the culprit...
Background— We previously demonstrated that ischemic postconditioning decreases creatine kinase release, a surrogate marker for infarct size, in patients with acute myocardial infarction. Our objective was to determine whether could afford (1) persistent size limitation and (2) an improved recovery of contractile function several months after Methods Results— Patients presenting within 6 hours the onset chest pain, suspicion first ST-segment–elevation infarction, whom clinical decision made...
Background— Opening of the mitochondrial permeability transition pore (mPTP) is a crucial event in lethal reperfusion injury. Phosphorylation (inhibition) glycogen synthase kinase-3β (GSK3β) has been involved cardioprotection. We investigated whether phosphorylated GSK3β may protect heart via inhibition mPTP opening during postconditioning. Methods and Results— Wild-type transgenic GSK3β-S9A mice (the cardiac activity which cannot be inactivated) underwent 60 minutes ischemia 24 hours...
Chronic obstructive pulmonary disease (COPD) is a highly prevalent and devastating condition for which no curative treatment available. Exaggerated lung cell senescence may be major pathogenic factor. Here, we investigated the potential role mTOR signaling in alterations COPD using tissue derived cultured cells from patients with age- sex-matched control smokers. Cell was linked to activation, inhibition by low-dose rapamycin prevented inhibited proinflammatory senescence-associated...
Patent foramen ovale (PFO)-associated strokes comprise approximately 10% of ischemic in adults aged 18 to 60 years. While device closure decreases stroke recurrence risk overall, the best treatment for any individual is often unclear.To evaluate heterogeneity effect PFO on based previously developed scoring systems.Investigators Systematic, Collaborative, Closure Evaluation (SCOPE) Consortium pooled patient data from all 6 randomized clinical trials that compared plus medical therapy vs...
The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19). Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or indirectly related to the intense systemic inflammatory immune responses are characteristic features of severe COVID-19. Pre-existing disease load linked myocardial injury worse outcomes. vascular response cytokine production interaction between acute respiratory syndrome coronavirus-2 (SARS-CoV-2)...
Background: Senescent cells (SCs) are involved in proliferative disorders, but their role pulmonary hypertension remains undefined. We investigated SCs patients with arterial and the of animal models. Methods: senescence (p16, p21) DNA damage (γ-H2AX, 53BP1) markers murine monitored p16 activation by luminescence imaging p16-luciferase (p16 LUC/+ ) knock-in mice. SC clearance was obtained a suicide gene promoter–driven killer construct p16-ATTAC mice), senolytic drugs (ABT263 cell-permeable...
Plasma levels of the vasoconstrictor peptide endothelin (ET) are increased in chronic heart failure (CHF), and ET a major predictor mortality this disease. Thus, may play deleterious role CHF. The purpose study was to assess effects treatment with receptor antagonist bosentan rat model CHF.Rats were subjected coronary artery ligation treated for 2 or 9 months placebo (30 100 mg x kg(-1) d(-1)). Bosentan markedly survival (after months: untreated, 47%; bosentan, 65%; P<.01). Throughout...